An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
Latest Information Update: 19 Jul 2024
Price :
$35 *
At a glance
- Drugs Upadacitinib (Primary) ; Upadacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SELECT-YOUTH
- Sponsors AbbVie; AbbVie Germany
- 18 Jun 2024 Planned primary completion date changed from 17 Aug 2027 to 5 May 2027.
- 17 May 2024 Planned End Date changed from 17 Aug 2027 to 5 May 2027.
- 17 May 2024 Status changed from recruiting to active, no longer recruiting.